当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析 - 现金流量表

上海医药

(601607)

  

流通市值:413.08亿  总市值:791.71亿
流通股本:19.33亿   总股本:37.05亿

现金流量表

报告期2024-09-302024-06-302024-03-312023-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金216,241,126,794.79143,040,840,673.3566,602,368,417.66283,639,391,269.47
收到的税费返还161,365,821.57109,651,206.4534,893,033.21113,743,387.01
收到其他与经营活动有关的现金3,014,000,050.911,692,189,000.811,174,472,290.33,030,275,784.49
经营活动现金流入的平衡项目0000
经营活动现金流入小计219,416,492,667.27144,842,680,880.6167,811,733,741.17286,783,410,440.97
购买商品、接受劳务支付的现金192,621,520,661.57127,982,487,400.7464,511,143,499.18251,978,264,993.59
支付给职工以及为职工支付的现金6,829,300,693.725,633,875,615.092,640,098,105.529,896,044,336.21
支付的各项税费5,770,527,692.33,763,146,129.922,067,750,418.447,497,835,891.88
支付其他与经营活动有关的现金11,412,179,163.426,947,868,351.834,066,341,430.6712,179,745,492.19
经营活动现金流出的平衡项目0000
经营活动现金流出小计216,633,528,211.01144,327,377,497.5873,285,333,453.81281,551,890,713.87
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额2,782,964,456.26515,303,383.03-5,473,599,712.645,231,519,727.1
二、投资活动产生的现金流量:
收回投资收到的现金17,454,567,00011,350,000,00010,050,000,00026,878,643,654.99
取得投资收益收到的现金971,322,262.61701,767,577.55120,895,726.03982,754,122.37
处置固定资产、无形资产和其他长期资产收回的现金净额159,079,166.98138,689,186.29815,734.76179,147,386.52
处置子公司及其他营业单位收到的现金净额12,364,306.65-11,514,306.65500,000
收到的其他与投资活动有关的现金756,787,587.49705,238,031.66348,516,368.371,268,304,839.07
投资活动现金流入的平衡项目0000
投资活动现金流入小计19,354,120,323.7312,895,694,795.510,531,742,135.8129,309,350,002.95
购建固定资产、无形资产和其他长期资产支付的现金1,835,291,094.21,393,196,297.47871,616,895.892,970,610,219.58
投资支付的现金15,857,397,0008,400,000,0007,100,000,00027,376,650,000
取得子公司及其他营业单位支付的现金93,692,695.483,508,582.824,034,930.28357,077,909.96
支付其他与投资活动有关的现金1,209,757,790.34985,812,200714,357,790.971,096,884,711.93
投资活动现金流出的平衡项目0000
投资活动现金流出小计18,996,138,579.9410,862,517,080.298,690,009,617.1431,801,222,841.47
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额357,981,743.792,033,177,715.211,841,732,518.67-2,491,872,838.52
三、筹资活动产生的现金流量:
吸收投资收到的现金18,315,022.813,743,691.91-354,277,173.14
其中:子公司吸收少数股东投资收到的现金---247,857,740.02
取得借款收到的现金45,513,265,721.3535,603,636,632.0518,435,199,786.2264,196,587,074.89
发行债券收到的现金8,997,610,000.015,998,726,666.672,999,522,50014,996,763,333.32
收到其他与筹资活动有关的现金654,648,042.46126,620,00086,542,631.35164,138,149.09
筹资活动现金流入平衡项目0000
筹资活动现金流入小计55,183,838,786.6341,732,726,990.6321,521,264,917.5779,711,765,730.44
偿还债务支付的现金50,540,691,452.4135,828,520,541.9717,414,048,741.0272,338,337,862.02
分配股利、利润或偿付利息支付的现金3,431,566,587.41,102,901,126.35657,029,889.334,915,917,995.46
其中:子公司支付给少数股东的股利、利润310,114,905.19151,114,751.2897,808,995.85934,712,519.71
支付其他与筹资活动有关的现金1,074,804,786.251,038,205,257.32199,933,738.622,225,658,982.23
筹资活动现金流出平衡项目0000
筹资活动现金流出小计55,047,062,826.0637,969,626,925.6418,271,012,368.9779,479,914,839.71
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额136,775,960.573,763,100,064.993,250,252,548.6231,850,890.73
四、汇率变动对现金及现金等价物的影响-22,872,683.73-8,187,361.977,736,229.48-5,580,083.93
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额3,254,849,476.896,303,393,801.26-373,878,415.892,965,917,695.38
加:期初现金及现金等价物余额27,499,809,001.227,499,809,001.227,499,809,001.224,533,891,305.82
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额30,754,658,478.0933,803,202,802.4627,125,930,585.3127,499,809,001.2
补充资料:
净利润-3,597,363,036.62-5,166,570,284.26
资产减值准备-36,526,101.71-561,277,474.11
固定资产和投资性房地产折旧-604,856,357.33-1,115,950,314.3
无形资产摊销-198,802,167.05-380,603,239.09
长期待摊费用摊销-85,945,173.34-192,328,518.62
处置固定资产、无形资产和其他长期资产的损失--139,310,426.73--92,475,307.03
公允价值变动损失--114,288,629.44--404,731,380.72
财务费用-915,719,792.37-1,862,945,397.89
投资损失--342,020,635.74--175,997,919.6
递延所得税--69,992,479.12--194,790,792.3
其中:递延所得税资产减少--38,384,896.92--146,609,422.15
递延所得税负债增加--31,607,582.2--48,181,370.15
存货的减少-1,335,453,749.85--2,303,791,595.46
经营性应收项目的减少--7,868,733,874.13--6,432,413,771.71
经营性应付项目的增加-1,622,348,664.67-4,585,509,346.07
现金的期末余额-33,803,202,802.46-27,499,809,001.2
减:现金的期初余额-27,499,809,001.2-24,533,891,305.82
公告日期2024-10-302024-08-272024-04-272024-03-29
审计意见(境内)标准无保留意见
TOP↑